Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Cdc42 Inhibitor
CID44216842 is a selective inhibitor of the small GTPase Cdc42, acting primarily by disrupting its guanine nucleotide binding. It demonstrates potent inhibitory activity with EC50 values of 1.0 μM and 1.2 μM for wild-type Cdc42 and the Cdc42Q61L mutant, respectively, in GTP binding assays, and 0.3 μM and 0.5 μM in GDP binding assays. This compound is suitable for use as a molecular probe in studies related to Cdc42 signaling pathways and its role in cellular processes such as cytoskeletal dynamics and cell migration. -
KRAS G12D Inhibitor
AZD0022 is a selective and orally active inhibitor of the KRAS G12D mutant protein. It effectively disrupts the KRAS signaling pathway, demonstrating suppression of tumor growth in the GP2D xenograft model. This compound is relevant for research in cancer therapeutics, particularly for investigating KRAS-driven malignancies. -
KRAS Inhibitor
KRAS inhibitor-3 is a selective inhibitor of the KRAS protein, effectively targeting both wild-type and various oncogenic mutants, including KRAS G12C, G12D, and Q61H, with affinities ranging from 0.28 μM to 0.74 μM. This compound disrupts the interaction between KRAS and Raf, thereby influencing downstream signaling pathways critical for cell proliferation and survival. KRAS inhibitor-3 is a valuable tool for research applications focused on cancer biology and the development of targeted therapies for KRAS-driven malignancies. -
Cdc42/Rac1 Inhibitor
l-Naproxen is an enantiomer of (S)-Naproxen, functioning as an inhibitor of Cdc42 and Rac1 with EC50 values of 96 μM and 212 μM, respectively. It exhibits anti-tumor activity in addition to its role as a nonsteroidal anti-inflammatory drug (NSAID). This compound is valuable for research applications involving cellular signaling pathways, inflammation, and cancer biology. -
KRasG12C Inhibitor
CFL-137 is a potent inhibitor of KRasG12C, a pivotal mutation implicated in various cancers. This compound demonstrates significant antiproliferative activity, making it a valuable tool for studying oncogenic signaling pathways. CFL-137 holds promise for research applications focused on lung cancer and other KRas-driven malignancies. -
KRAS Inhibitor
KRAS Inhibitor-10 is a selective inhibitor targeting RAS proteins, with a strong emphasis on KRAS variants. This orally active compound demonstrates significant anti-cancer activity, making it suitable for research applications in various malignancies, including pancreatic cancer, breast cancer, multiple myeloma, leukemia, and lung cancer. KRAS Inhibitor-10 is derived from a tetrahydroisoquinoline structure and is detailed in patent WO2021005165 A1. -
KRASG12D Mutant Inhibitor
KRAS G12D-IN-29 is a selective inhibitor targeting the KRAS G12D mutant, known for its oral bioavailability. This compound effectively disrupts downstream signaling pathways associated with KRAS G12D, leading to a reduction in tumor cell proliferation. KRAS G12D-IN-29 shows potential for research applications focused on cancers driven by the KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. -
KRAS Inhibitor
KRAS Inhibitor-31 is a potent inhibitor targeting mutant forms of the KRAS protein, specifically KRAS G12D, G12C, and G12V, with KD (SPR) values of 0.019 nM, 0.019 nM, and 0.096 nM, respectively. This compound demonstrates significant biological activity in the inhibition of KRAS-driven signaling pathways, making it a valuable tool for research in cancer biology, particularly in the study of tumors harboring KRAS mutations. -
pan-KRAS Inhibitor
pan-KRAS-IN-2 is a potent pan-KRAS inhibitor with IC50 values of ≤ 10 nM against both wild-type and prevalent mutant forms of KRAS, including G12D, G12C, G12V, G12S, G12A, and Q61H, while exhibiting an IC50 > 10 μM for KRAS G13D. This compound is valuable for investigating KRAS-mediated cancers, specifically in pancreatic and colorectal cancer models, aiding in the understanding of tumor biology and potential therapeutic interventions. -
Rac1 Inhibitor
Rac1-IN-3 is an inhibitor of the Rac1 protein, exhibiting an IC50 of 46.1 μM. This compound effectively disrupts Rac1 signaling pathways, which are implicated in various cellular functions such as cytoskeletal dynamics and cell migration. Rac1-IN-3 is valuable for research applications focused on cancer biology, neurodegenerative diseases, and cardiovascular disorders, providing insights into the role of Rac1 in disease progression and therapeutic targeting. -
pan-KRAS Inhibitor
pan-KRAS-IN-18 is a pan-KRAS inhibitor targeting both KRAS wild-type and KRAS G12V, with IC50 values of 29 nM and 9 nM, respectively. This compound demonstrates significant antiproliferative activity in KRAS-mutant cell lines, making it a valuable tool for researchers studying KRAS-driven cancers. Its application is particularly relevant in the context of lung cancer research. -
KRAS G12C Inhibitor
Divarasib adipate is a potent and selective inhibitor of KRAS G12C with an IC50 of <0.01 μM. By covalently binding to the switch II pocket of KRAS G12C, Divarasib irreversibly stabilizes the protein in its inactive GDP-bound state. This compound is primarily utilized in research applications focused on cancer biology, particularly in studies targeting KRAS-driven tumors. -
KRAS(G12D) Inhibitor
MRTX-EX185 formic is a potent inhibitor of KRAS(G12D) with an IC50 of 90 nM. It effectively binds to both GDP-loaded and active GTP-bound states of KRAS, displaying broad-spectrum activity with additional IC50 values of 110, 290, 130, and 240 nM for KRAS WT, KRAS(G12C), KRAS(Q61H), and KRAS(G13D), respectively. MRTX-EX185 formic also shows affinity for GDP-loaded HRAS. This compound is valuable for investigating RAS-driven tumors, including pancreatic cancer, facilitating insights into therapeutic strategies targeting KRAS mutations. -
Pan-RAS Inhibitor
Pan-RAS-IN-3 is a pan-RAS inhibitor that targets various isoforms of the RAS protein family, known for their role in promoting cellular proliferation and survival. This compound exhibits significant biological activity in inhibiting the signaling pathways associated with melanoma and acute myeloid leukemia. It is a valuable tool for researchers investigating RAS-driven cancers and studying the therapeutic potential of targeting these oncogenic signaling pathways. -
KRAS Inhibitor
KRAS inhibitor-24 is a pyridopyrimidine compound that selectively inhibits KRAS with an IC50 of less than 100 nM for KRas G12V, KRas WT, and KRas G12R mutants. This compound demonstrates substantial biological activity in disrupting KRAS-mediated signaling pathways. KRAS inhibitor-24 is utilized in preclinical research to study KRAS-driven tumors and to investigate potential therapeutic strategies targeting KRAS mutations in various cancers. -
KRAS Inhibitor
(1R)-KRAS inhibitor-24 is a pyridopyrimidine compound that selectively inhibits KRAS, demonstrating an IC50 of less than 100 nM for KRas G12V, KRas Wild Type, and KRas G12R variants. This inhibitor serves as a valuable tool for research applications focused on KRAS-driven cancers, providing insights into signaling pathways and potential therapeutic modalities targeting this critical oncogene. -
KRAS G12D Inhibitor
KRAS G12D-IN-31 is a potent inhibitor of the KRAS G12D mutation, exhibiting an IC50 of less than 100 nM. It effectively inhibits the proliferation of RAS-dependent cancer cells, including those harboring KRAS G12C, KRAS G12D, KRAS G12V, and KRASWT. This compound is particularly valuable for research applications involving non-small cell lung cancer, gastric cancer, colon cancer, and malignant melanoma, facilitating the exploration of KRAS-targeted therapies. -
KRAS(G12D) Inhibitor
TH-Z827 is a selective inhibitor of the KRAS(G12D) mutant, demonstrating an IC50 of 2.4 μM. This compound does not interact with wild-type KRAS or the KRAS(G12C) variant. TH-Z827 effectively disrupts the interaction between KRAS(G12D) and CRAF, with an IC50 value of 42 μM, making it a valuable tool for studying KRAS-driven cancers and developing targeted therapies. -
KRAS G12D Inhibitor
KRAS G12D Inhibitor 3 TFA is a selective inhibitor targeting the KRAS G12D mutation, exhibiting an IC50 of less than 500 nM. This compound demonstrates significant antitumor activity, making it a valuable tool in cancer research related to KRAS-driven malignancies. Additionally, KRAS G12D Inhibitor 3 TFA features an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), thus facilitating the development of bioconjugates and other applications in chemical biology. -
Lbc-RhoA Interaction Inhibitor
(E/Z)-ZINC09659342 is a potent inhibitor of the Lbc-RhoA protein interaction, impacting RhoA-mediated cellular signaling pathways. This compound is valuable for studies focused on RhoA's role in cell adhesion, migration, and cytoskeletal dynamics. It serves as a useful tool for researchers investigating the molecular mechanisms of various diseases associated with RhoA dysregulation. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 14 is a potent inhibitor specifically targeting the KRAS G12C mutation, with an IC50 value of 18 nM. This compound effectively disrupts the activity of the KRAS protein, making it a valuable tool for studies on cancer biology, particularly in models of tumors driven by KRAS mutations. Its application extends to drug discovery and development efforts aimed at novel therapeutic strategies for KRAS-driven malignancies. -
MRTF/SRF Inhibitor
MRTF/SRF-IN-1 is a selective inhibitor of myocardin-related transcription factor and serum response factor (MRTF/SRF). This compound is utilized in research aimed at understanding the role of MRTF/SRF in cancer progression and fibrotic diseases. It has potential applications in studying molecular pathways associated with cellular proliferation and fibrosis. -
Farnesyl Transferase Inhibitor
BMS-214662 hydrochloride is a potent farnesyltransferase inhibitor that disrupts the prenylation of Ras proteins, preventing their localization and function at the cell membrane. This inhibition leads to significant anti-tumor activity, making it a valuable tool for cancer research. The compound demonstrates a high affinity for H-Ras with an IC50 of 1.3 nM and for K-Ras with an IC50 of 8.4 nM, highlighting its potential in studying tumorigenesis associated with Ras signaling pathways. -
GGTase I Inhibitor
GGTI-286 is a selective inhibitor of geranylgeranyl transferase I (GGTase I) with an IC50 of 2 μM, demonstrating 25-fold increased potency compared to its methyl ester derivative. It effectively inhibits the geranylgeranylation of Rap1A while displaying a lower impact on the farnesylation of H-Ras, with IC50 values of 2 μM and >30 μM, respectively. Additionally, GGTI-286 shows strong inhibition of oncogenic K-Ras4B stimulation, with an IC50 of 1 μM, making it a valuable tool for research in cancer biology and signaling pathways. -
Ras Inhibitor
KRAS G12D inhibitor 5 is a selective inhibitor targeting the mutated KRAS G12D protein, a key driver in various malignancies, including pancreatic cancer. This compound is valuable in research applications focusing on the therapeutic mechanisms underlying KRAS-driven tumorigenesis and may help elucidate the pathways involved in cancer progression and resistance. -
KRAS G12C Inhibitor
Sosimerasib is an orally active inhibitor targeting KRAS G12C mutations. It exhibits significant functional inhibitory effects on mutant KRAS G12C proteins, making it a valuable tool for studying signaling pathways involved in cancer progression. This compound is particularly relevant for research applications focused on non-small cell lung cancer. -
KRAS(G12D) Inhibitor
MRTX-EX185 is a selective inhibitor of KRAS(G12D) with an IC50 of 90 nM, effectively binding to both GDP-loaded and active GTP-bound states of KRAS. This compound demonstrates broad-spectrum activity against various KRAS mutations, including KRAS WT, KRAS (G12C), KRAS (Q61H), and KRAS (G13D), with IC50 values ranging from 110 nM to 290 nM. Additionally, MRTX-EX185 interacts with GDP-loaded HRAS. This reagent is valuable for investigating RAS-driven tumors, particularly in the context of pancreatic cancer research. -
K-Ras-G12D Inhibitor
(R)-G12Di-7 is a covalent inhibitor specifically targeting K-Ras-G12D. This compound selectively binds to the K-Ras-G12D·GDP and K-Ras-G12D·GppNHp complexes, effectively labeling them. (R)-G12Di-7 demonstrates significant inhibitory activity against cancer cells harboring the G12D mutation, making it a valuable tool for research into K-Ras-related oncogenic signaling and potential therapeutic interventions. -
KRASG12C Inhibitor
(7R)-Elisrasib is a selective inhibitor targeting the KRASG12C mutation, a key driver in various cancers. This compound demonstrates potent antitumor activity, effectively inhibiting tumor growth in preclinical mouse models. It is primarily used in cancer research focused on KRAS-driven tumors and aids in the investigation of targeted therapies for oncogenic mutations. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 28 is a selective inhibitor targeting the KRAS G12C mutation, exhibiting an IC50 of 57 nM. This compound demonstrates significant antitumor activity and is utilized in research focusing on KRAS-driven cancers. Its applications include investigating the therapeutic potential of KRAS inhibition in various oncological studies. -
RAS GTPase Inhibitor
RAS GTPase inhibitor 1 is a specific inhibitor targeting RAS GTPase, known for its significant anti-tumor activity. This compound demonstrates an effective EC50 of less than 1 μM in facilitating nucleotide exchange and an IC50 of less than 1 μM in H727 cancer cells. It is valuable for research applications aimed at understanding RAS signaling pathways and developing targeted cancer therapies. -
Rac GTPase-p67 Inhibitor
p67phox-IN-1 is a specific inhibitor of the interaction between Rac GTPase and the p67phox protein. This compound interferes with the activation of the NADPH oxidase complex, thereby modulating reactive oxygen species production. p67phox-IN-1 serves as a valuable tool in research related to oxidative stress, inflammation, and redox signaling pathways. Its utility extends to studies exploring the role of Rac GTPases in various physiological and pathological processes. -
GIT1/β-Pix PPI Inhibitor
PPI-GIT1/β-Pix PPI-IN-1 is a potent inhibitor of the GIT1/β-Pix protein-protein interaction, exhibiting a KD value of 7.7 µM. By disrupting the GIT/PIX interaction, this compound effectively modulates the activation of downstream Rho GTPases Rac1 and Cdc42, which are critical in various signaling pathways. PPI-GIT1/β-Pix PPI-IN-1 is particularly relevant in cancer research, demonstrating significant inhibitory effects on the metastasis of gastric cancer. -
KRAS G12D Inhibitor
KRAS G12D Inhibitor 1 is a potent inhibitor targeting the KRAS G12D mutant with an IC50 of 0.4 nM. It effectively inhibits KRAS G12D-mediated ERK phosphorylation, exhibiting an IC50 of 0.8 nM. This compound is valuable in research focused on cancers driven by KRAS G12D mutations, including pancreatic ductal adenocarcinoma and colorectal cancer. -
KRAS G12D Inhibitor
(R)-KRAS G12D inhibitor 28 hydrochloride dihydrate specifically targets the KRAS G12D mutant protein, functioning as an effective inhibitor. This compound demonstrates significant potential in cancer research, particularly in studies focused on KRAS-driven malignancies. Its application can aid in the investigation of KRAS signaling pathways and the development of targeted therapies for KRAS-related tumors. -
KRAS G12C Inhibitor
KRASG12C IN-13 is a selective inhibitor targeting the KRAS G12C mutation. This compound demonstrates significant biological activity against advanced solid tumors, particularly non-small cell lung cancer and colorectal cancer. Researchers can utilize KRASG12C IN-13 to investigate therapeutic strategies and resistance mechanisms associated with KRAS-driven malignancies. -
Kras4B G12D Inhibitor
Kras4B G12D-IN-1 is a selective inhibitor of the Kras4B G12D mutant, targeting its oncogenic activity. This compound demonstrates significant anticancer properties by reducing Kras protein expression in mouse embryonic fibroblasts (MEF) harboring the Kras4B G12D mutation. Kras4B G12D-IN-1 is relevant for research investigating Kras-driven cancers and the development of targeted therapies. -
KRASG12D Inhibitor
KRASG12D-IN-3 is a potent inhibitor that specifically targets the KRASG12D mutation. It demonstrates significant anti-proliferative effects on AGS and AsPC-1 cell lines, with IC50 values of 0.38 nM and 1.23 nM, respectively. This compound is valuable for research applications focused on the role of KRAS mutations in cancer biology and therapeutic development. -
NRAS G12D Inhibitor
IACS-56676 is a selective inhibitor of the NRAS G12D mutation, with a binding affinity (Kd) of 0.031 μM. It stabilizes the p-loop and preserves critical interactions with key residues, including Asp12, Gly60, and Asp69, allowing for its specificity toward NRAS G12D while sparing wild-type KRAS through targeting Leu95. This compound is applicable in research focusing on melanoma, hematologic malignancies, and thyroid cancer, providing a valuable tool for investigating targeted therapies in these contexts. -
KRAS G12C Inhibitor
(4R)-BBO-8520 is a selective inhibitor of the KRAS G12C mutant. This compound effectively impedes the KRAS G12C (ON) signaling, thereby inhibiting cell proliferation by blocking the interaction with GTP. Additionally, (4R)-BBO-8520 disrupts the RAS-RAF1 interaction, facilitating the return of KRAS G12C to its inactive (OFF) state. It is particularly valuable for research applications focused on cancer biology and therapeutics targeting KRAS-driven malignancies. -
KRAS(G12C) Inhibitor
Spiclomazine is a selective inhibitor of mutant KRAS(G12C), targeting KRAS-driven pancreatic cancer. This compound effectively reduces KRas-GTP levels and inhibits downstream RAS-mediated signaling pathways. In preclinical studies, Spiclomazine demonstrates significant tumor progression inhibition in mouse renal capsule xenotransplantation models, making it a valuable tool for researching therapeutic strategies against KRAS-driven malignancies. -
GGTase I Inhibitor
GGTI-286 hydrochloride is a selective inhibitor of geranylgeranyltransferase I (GGTase I) with a potency that is 25-fold greater than the methyl ester of FTI-276 (IC50 = 2 μM). This compound demonstrates a strong preference for inhibiting the geranylgeranylation of Rap1A over the farnesylation of H-Ras in NIH3T3 cells (IC50s = 2 μM and >30 μM, respectively). Additionally, GGTI-286 hydrochloride effectively inhibits the stimulation of oncogenic K-Ras4B, with an IC50 of 1 μM, making it a valuable tool for research in cancer biology and signal transduction pathways. -
Ra Inhibitor
K-Ras-IN-4 is a potent K-Ras inhibitor that specifically targets the K-Ras oncogene, a critical player in cancer cell signaling. This compound effectively impedes K-Ras-mediated signaling pathways, thereby attenuating cell proliferation and survival in K-Ras-driven tumors. K-Ras-IN-4 is utilized in research focused on understanding K-Ras biology and developing targeted therapies for cancers associated with K-Ras mutations. -
KRAS G12C Inhibitor
KRAS inhibitor-6 is a potent inhibitor of the KRAS G12C mutation, specifically designed to selectively target and inhibit this oncogenic driver. Its mechanism of action involves binding to the active site of the mutant KRAS protein, effectively disrupting downstream signaling pathways involved in cellular proliferation and survival. This compound has significant implications for cancer research and therapeutic applications, particularly in the treatment of KRAS-driven tumors. -
KRAS G12C Inhibitor
KRAS inhibitor-8 is a selective inhibitor targeting the KRAS G12C mutation, known for its role in various cancers. This compound demonstrates significant biological activity by effectively disrupting KRAS signaling pathways, leading to reduced tumor growth in KRAS-driven malignancies. KRAS inhibitor-8 is ideal for research in cancer biology and drug discovery focused on mutant KRAS therapeutics. -
KRAS G12C Inhibitor
KRAS inhibitor-7 is a selective inhibitor targeting the KRAS G12C mutant protein. This compound demonstrates significant inhibition of KRAS G12C activity, making it a valuable tool for studying oncogenic signaling pathways involving KRAS mutations. Its primary applications include cancer research, particularly in the development of targeted therapies for KRAS-driven tumors. -
Ras Inhibitor
KRAS mutant protein inhibitor 1 selectively targets and inhibits the activity of mutant KRAS proteins. Its primary mechanism involves disruption of KRAS-mediated signaling pathways, which are critical in various cancers. This compound is valuable for research applications focused on understanding the role of KRAS mutations in tumorigenesis and exploring potential therapeutic strategies for KRAS-driven malignancies. -
KRAS G12C Inhibitor
KRAS G12C Inhibitor 32 is a potent inhibitor targeting the KRAS G12C mutation. This eight-membered heterocyclic compound demonstrates strong inhibitory activity, which is critical for studies focusing on cancer therapeutics associated with KRAS mutations. It is primarily utilized in research exploring the mechanisms of KRAS-driven malignancies and the development of targeted therapies. -
KRAS G12C Inhibitor
KRAS G12C inhibitor 18 is a selective inhibitor targeting the KRAS G12C mutation. This compound exhibits significant anti-tumor activity, making it valuable for cancer research focused on KRAS-driven malignancies. It is suitable for studies investigating the therapeutic potential of KRAS inhibition in oncogenesis and treatment resistance. -
KRas Inhibitor
KRAS Inhibitor-20 is a small molecule inhibitor targeting the oncogenic mutant KRasG12C. It demonstrates potent inhibitory activity with an IC50 value of less than 10 nM, making it an effective tool for studying KRas-driven malignancies. This compound is valuable for research applications focused on cancer biology, offering insights into therapeutic strategies for KRas-related tumors.
